Gyeonggi-do, South Korea

Woul Seong Park



 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Woul Seong Park: Innovator in Histamine Receptor Inhibitors

Introduction

Woul Seong Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target the histamine 4 receptor. His work is crucial for advancing treatments for various inflammatory and allergic conditions.

Latest Patents

Woul Seong Park holds a patent for "Substituted tricyclic heterocycles as histamine 4 receptor inhibitors." This invention relates to novel heterocyclic compounds that are useful in preparing drugs for the treatment of diseases associated with various functions of the histamine 4 receptor. The drugs developed from this invention are particularly beneficial for treating inflammatory diseases, allergies, pain, and a range of other medical conditions, including asthma, rheumatoid arthritis, and multiple sclerosis.

Career Highlights

Woul Seong Park is currently associated with C&C Research Laboratories, where he continues to innovate in the pharmaceutical sector. His research focuses on creating effective treatments that can alleviate the symptoms of various chronic conditions.

Collaborations

He has collaborated with notable colleagues, including Pil Su Ho and Dong Oh Yoon, to further enhance the research and development of new therapeutic compounds.

Conclusion

Woul Seong Park's contributions to the field of histamine receptor inhibitors exemplify the impact of innovative research in medicine. His work not only advances scientific knowledge but also holds the potential to improve the quality of life for many patients suffering from chronic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…